Imigran (Sumatriptan Succinate)

Sumatriptan binds to 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This action causes vasoconstriction of dilated vessels and blocks the release of pain‑triggering neuropeptides, interrupting the migraine cascade.

The dose of Imigran is determined by the prescribing clinician based on the patient’s individual needs, severity of migraine, and prior response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety of sumatriptan in pregnancy and lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Imigran.

To order Imigran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imigran (sumatriptan) is one of the first‑generation triptans and is widely studied for migraine relief. Compared with newer agents, it has a well‑characterized efficacy and safety profile, but individual response varies, so clinicians may choose alternative triptans based on patient tolerance, speed of onset, or specific contraindications.

Imigran tablets should be stored at ambient temperature, below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and keep out of reach of children.

Imigran is taken orally as a tablet. The tablet should be swallowed whole with water, preferably at the first sign of a migraine attack. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious risks include coronary vasospasm, myocardial infarction, severe hypertension, stroke, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience chest pain, severe headache, visual changes, or signs of an allergic reaction.

Imigran is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, peripheral vascular disease, severe hepatic impairment, or known hypersensitivity to sumatriptan. It should also be avoided in individuals currently taking MAO inhibitors or ergot alkaloids.